Journal article
The effect of low-dose colchicine in patients with stable coronary artery disease: The LoDoCo2 trial rationale, design, and baseline characteristics
Abstract
Because patients with stable coronary artery disease are at continued risk of major atherosclerotic events despite effective secondary prevention strategies, there is a need to continue to develop additional safe, effective and well-tolerated therapies for secondary prevention of cardiovascular disease. RATIONALE AND DESIGN: The LoDoCo (Low Dose Colchicine) pilot trial showed that the anti-inflammatory drug colchicine 0.5 mg once daily appears …
Authors
Nidorf SM; Fiolet ATL; Eikelboom JW; Schut A; Opstal TSJ; Bax WA; Budgeon CA; Tijssen JGP; Mosterd A; Cornel JH
Journal
American Heart Journal, Vol. 218, , pp. 46–56
Publisher
Elsevier
Publication Date
December 2019
DOI
10.1016/j.ahj.2019.09.011
ISSN
0002-8703
Associated Experts
Fields of Research (FoR)
Sustainable Development Goals (SDG)
Medical Subject Headings (MeSH)
AdultAgedAged, 80 and overAnti-Inflammatory Agents, Non-SteroidalAtherosclerosisAustraliaCardiovascular DiseasesClinical Trial Protocols as TopicColchicineCoronary Artery DiseaseDouble-Blind MethodDrug Administration ScheduleDrug RepositioningFemaleHumansMaleMiddle AgedMyocardial InfarctionNetherlandsPercutaneous Coronary InterventionSecondary PreventionStrokeTubulin Modulators